Note: Because AOD-9604 does not affect glucose metabolism or IGF-1, monitoring requirements are simpler than with growth hormone therapy
The most common experiences include slight nausea (particularly with first doses), minor fatigue or drowsiness, temporary dizziness, injection site reactions like mild redness or itching, and sleep disturbances (usually with evening dosing)
By reducing inflammatory markers and supporting tissue comfort, BPC 157 peptide may remove obstacles to deep, restorative sleep
short rodent studies have not reported overt tumors, but long-term and human data are absent [5]
Leyendecker G, Kunz G, Herbertz M, Beil D, Huppert P, Mall G, et al